Navigation Links
Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
Date:12/18/2007

EAST SETAUKET, N.Y., Dec. 18 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) a developer of improved methods for both detection and treatment of cancer, announced the closing of a private placement. In the placement, Lixte sold 1,000,000 shares of its Common Stock at a price of $0.65 per share resulting in gross proceeds of $650,000. WestPark Capital, Inc. acted as placement agent and received $65,000 in commissions and $26,000 representing a non-accountable expense fee. Lixte also issued to WestPark five year warrants to purchase up to 100,000 shares of the Company's Common Stock and five year incentive warrants to purchase up to an additional 20,000 shares, all such warrants to be exercisable at $0.65 per share.

Lixte agreed to file a registration statement with the SEC covering resale of the shares upon written request from holders who represent at least 50% of the shares. Lixte also granted to the holders piggyback registration rights.

John Kovach, Lixte's President, stated that Lixte intends to use the net proceeds to pursue development of proprietary compounds for the submission of an IND to the Food & Drug Administration for a Phase I clinical trial, and for working capital.

The offer and sale of the shares sold were not registered under the Securities Act of 1933, as amended in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act and Regulation D promulgated thereunder. The shares sold by Lixte may not be reoffered or sold in the United States by the holders in the absence of an effective registration statement, or exemption from the registration requirements, under the Securities Act.

About Lixte

Lixte is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, the Company develops new chemotherapy drugs targeting molecular abnormalities of common human cancers. Over the past year, based on the
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 Research and ... the addition of the "Global Next Generation ... The global next generation sequencing market ... the period 2014-2019 This report covers ... the global next generation sequencing market for the ...
(Date:5/21/2015)... SEATTLE , May 21, 2015 Sarcos ... sensors and medical devices, announced today the appointment of ... Officer and head of Corporate Development effective immediately.  Woo ... development and finance roles, including positions at UBS Investment ... Woo will be located in Sarcos, Seattle ...
(Date:5/21/2015)... , May 21, 2015 /CNW/ - Canadians face wait times of ... lifesaving medicines in public drug plans, according to a new ... Canada 16 out of 18 similar OECD ... 23% of 141 Health Canada-approved new medicines were included in public ... on this front," said Brett Skinner , Rx&D Executive Director, ...
Breaking Medicine Technology:Global Next Generation Sequencing Market 2015-2019 2Sarcos Corp. Announces Preston Woo as CFO and Head of Corporate Development 2Canadians lagging well behind similar countries on access to new medicines: report 2Canadians lagging well behind similar countries on access to new medicines: report 3
... N.Y. Feb. 7, 2011 BioSpecifics Technologies Corp. (Nasdaq: ... biopharmaceutical company developing first in class collagenase-based products, today ... Rights Agreement (the "Rights Agreement"), adopted May 14, 2002 ... The Amendment increases the ownership threshold for determining ...
... start-up, UrgentRx , today announced the launch of ... credit card-sized packets, including UrgentRx Aspirin to Go ... first aid.  February is the American Heart Association,s ... UrgentRx Aspirin to Go timely as research supports the ...
Cached Medicine Technology:UrgentRx Launches Line of Innovative and Portable, Fast-Acting Medications Across Colorado 2UrgentRx Launches Line of Innovative and Portable, Fast-Acting Medications Across Colorado 3
(Date:5/22/2015)... 2015 The dentist in ... that they are now offering complimentary consultations to ... treatments. At consultations, patients can discuss their candidacy ... certain treatments can achieve and whether alternative options ... initial appointment. If treatments are chosen, patients can ...
(Date:5/22/2015)... 22, 2015 Wimbledon Health Partners, the ... (EKG), echocardiogram and NCV testing , is proud ... respected All American National athlete, to the Wimbledon Athletics ... the high level of testing and information it provides ... their athletic trainers, this way they can focus on ...
(Date:5/22/2015)... May 22, 2015 In April 2006, ... the past 9 years they have concentrated their focus ... States and Canada. Because of this growth and their ... corporate offices in Denver, Colorado, Cleveland, Ohio, Houston, Texas ... in opening new dental offices, dental start ups, orthodontic ...
(Date:5/22/2015)... May 22, 2015 In efforts to ... the section containing particular muscles stretches has been a ... 50% of stretches now complete, Chunk Fitness envisions a ... to be filmed and released at a later point ... found here: http://www.chunkfitness.com/stretches . , About the Company: ...
(Date:5/21/2015)... New York, New York (PRWEB) May 21, 2015 ... and distributor of patented products, launches the Troll Motor ... more convenient way of boating. , "The recreational boating ... says Scott J. Cooper, CEO and Creative Director of ... the water in record numbers and predicts continued steady ...
Breaking Medicine News(10 mins):Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 3
... ... and distribute the QuickMAR e-charting software with its electronic medication management systems. , ... (PRWEB) January 26, 2010 ... easily and accurately manage patient medications, with today’s announcement of a joint distribution agreement ...
... publication in The Endocrine Society,s Journal of Clinical ... commonly used forms of antidepressant drugs may experience delayed ... to achieve their breastfeeding goals. Breastfeeding benefits ... milk is easy to digest and contains antibodies that ...
... ... tips for safer driving on icy highways. , ... New York, NY (PRWEB) January 26, 2010 -- When rain falls or ... personal injury attorney says., , ,“Black ice is as dangerous as it is difficult to ...
... ... is pleased to announce that they are now offering Trek’s Ride+ electric assist bikes to their ... and battery, Trek Travel is opening up a new world of cycling vacations to a wider ... ...
... ... an industry leader in Continuous Process Improvement (CPI) Training and Certification, took ... battle tough economic times, they made their On Demand Lean Six Sigma ... hundreds of organizations to learn the basics of Lean Six Sigma, but ...
... , , WASHINGTON , Jan. 25 ... guilty today for her role in a Detroit -area home ... of the Criminal Division; U.S. Attorney for the Eastern District ... Arena of the FBI,s Detroit Field Office; and Special Agent in ...
Cached Medicine News:Health News:Medicine-On-Time Partners With QuickMAR to Streamline Medication Management and Improve Patient Care 2Health News:Medicine-On-Time Partners With QuickMAR to Streamline Medication Management and Improve Patient Care 3Health News:Common antidepressant drugs linked to lactation difficulties in moms 2Health News:Driving Danger -- Black Ice Poses Menace on Frigid NY Roadways, New York Attorney Steven J. Schwartzapfel Says 2Health News:Driving Danger -- Black Ice Poses Menace on Frigid NY Roadways, New York Attorney Steven J. Schwartzapfel Says 3Health News:Driving Danger -- Black Ice Poses Menace on Frigid NY Roadways, New York Attorney Steven J. Schwartzapfel Says 4Health News:Trek Travel Introduces Trek's Ride+ Electric Assist Bikes to Cycling Vacations 2Health News:Mountain Home Experiences a Huge Response to Their Ground Breaking Free Lean Six Sigma Certification Offer 2Health News:Physical Therapist Pleads Guilty in Connection with Detroit Home Health Care Fraud Scheme 2Health News:Physical Therapist Pleads Guilty in Connection with Detroit Home Health Care Fraud Scheme 3
... ENA Profile-6 ELISA test system is a ... antibodies to Jo-1, Sm, Sm/RNP, SSA, SSB, ... according to the directional insert, the results ... the diagnosis and treatment of autoimmune connective ...
Inquire...
... The K-ASSAY Microalbumin Urine Controls ... to use liquid requiring no ... prepared from human urine, fortified ... albumin and creatinine. Preservatives including ...
The K-ASSAY ITA Lyophilized Multi-Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assays for the li...
Medicine Products: